Kala Bio (KALA) Payables (2016 - 2026)
Kala Bio (KALA) posted Payables of $1.0 million for Q1 2026, up 5.88% sequentially from $986000.0 in Q4 2025, and up 12.14% YoY from $931000.0 in Q1 2025.
Kala Bio (KALA) Payables (2016 - 2026) Analysis & Trends
Kala Bio has reported Payables for 11 years, with the latest figure at $1.0 million in Q1 2026.
- Quarterly Payables rose 12.14% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (up 12.14% YoY) and the FY2025 annual result came in at $986000.0, up 57.01% from the prior year.
- Payables improved to $1.0 million in Q1 2026 per KALA's latest filing, from $986000.0 in the prior quarter.
- Over five years, Payables peaked at $10.5 million in Q2 2022 and troughed at $628000.0 in Q4 2024.
- A 5-year average of $2.2 million and a median of $919000.0 in 2023 frame the typical range for Payables.
- The sharpest annual moves came in 2022 and 2023: Payables soared 270.68% in 2022, then tumbled 92.79% in 2023.
- Over 5 years, Payables stood at $2.8 million in 2022, then plunged by 67.55% to $919000.0 in 2023, then slumped by 31.66% to $628000.0 in 2024, then surged by 57.01% to $986000.0 in 2025, then advanced by 5.88% to $1.0 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $1.0 million, $986000.0, and $917000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | Kala Bio | 9.87 Mn | 9.87 Mn | - | 1.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.04 Mn |
| Dec 31, 2025 | 986,000.00 |
| Sep 30, 2025 | 917,000.00 |
| Jun 30, 2025 | 658,000.00 |
| Mar 31, 2025 | 931,000.00 |
| Dec 31, 2024 | 628,000.00 |
| Sep 30, 2024 | 711,000.00 |
| Jun 30, 2024 | 665,000.00 |
| Mar 31, 2024 | 732,000.00 |
| Dec 31, 2023 | 919,000.00 |
| Sep 30, 2023 | 787,000.00 |
| Jun 30, 2023 | 760,000.00 |
| Mar 31, 2023 | 997,000.00 |
| Dec 31, 2022 | 2.83 Mn |
| Sep 30, 2022 | 7.35 Mn |
| Jun 30, 2022 | 10.54 Mn |
| Mar 31, 2022 | 6.22 Mn |
| Dec 31, 2021 | 4.90 Mn |
| Sep 30, 2021 | 5.85 Mn |
| Jun 30, 2021 | 2.84 Mn |